Key terms
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CPRX news
Mar 28
8:11am ET
Catalyst Pharmaceuticals announces support for inaugural LEMS awareness day
Mar 18
4:55am ET
Catalyst Pharmaceuticals management to meet with Oppenheimer
Mar 14
7:40am ET
Analysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)
Mar 14
7:20am ET
Analysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)
Mar 13
4:07pm ET
Catalyst Pharmaceuticals management to meet with Oppenheimer
Mar 13
7:58am ET
Catalyst Pharmaceuticals announces commercial availability of AGAMREE
Mar 12
6:40am ET
‘Time to Hit Buy,’ Says Bank of America About These 3 Stocks
Mar 07
9:40am ET
BofA starts ‘unique aggregator’ Catalyst Pharmaceuticals with a Buy
Mar 07
7:55am ET
Catalyst Pharmaceuticals initiated with a Buy at BofA
Mar 01
6:27am ET
Catalyst Pharma’s Strategic Advancements and Market Opportunities Bolster Buy Rating
Feb 29
8:06am ET
Oppenheimer Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
Feb 29
7:24am ET
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Catalyst Pharma (CPRX) and Viridian Therapeutics (VRDN)
Feb 29
7:22am ET
Catalyst Pharma (CPRX) Receives a Rating Update from a Top Analyst
Feb 28
6:05pm ET
Catalyst Pharmaceuticals sees FY24 revenue $455M-$475M, consensus $463.19M
Feb 28
6:04pm ET
Catalyst Pharmaceuticals reports Q4 adjusted EPS 56c, consensus 26c
Feb 21
4:56pm ET
Catalyst Pharma Announces Promising Duchenne Drug Study Results
Feb 21
9:09am ET
Catalyst announces publication of Santhera’s VISION-DMD study results
Jan 31
5:55am ET
Catalyst Pharmaceuticals management to meet with Oppenheimer
Jan 30
4:55am ET
Catalyst Pharmaceuticals management to meet with Oppenheimer
Jan 24
8:17am ET
Catalyst Pharmaceuticals management to meet with Oppenheimer
Jan 10
7:18am ET
Piper Sandler Remains a Buy on Catalyst Pharma (CPRX)
Jan 08
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Jan 05
6:13am ET
Catalyst Pharmaceuticals 10M share Spot Secondary priced at $15.00
Jan 04
8:52pm ET
Catalyst Pharmaceuticals prices $150M offering at $15 per share, Bloomberg says
Jan 04
4:51pm ET
Catalyst Pharmaceuticals announces $150M offering of common stock
No recent press releases are available for CPRX
CPRX Financials
Key terms
Ad Feedback
CPRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CPRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
